CEBPA and acute myeloid leukemia: (3) Additional evidence of the superiority of HSCT in patients with intermediate-risk acute myeloid leukemia (AML), positive minimal (or measurable) residual disease (MRD+) favorable-risk AML (CBFb-MYH11+, biallelic mutated CEBPA), and standard-risk Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (Ph-ALL) has emerged.